Overview Dividends

(CLX) The Clorox - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1890541097

Bleach, Disinfectants, Litter, Dressings, Filters

Household Products
Market Cap in USD: 12,413m

IPO / Inception: 1983-03-21
Return 12m vs S&P 500: -43.1%

EPS (Earnings per Share)

EPS CAGR: 6.98%
EPS Trend: 46.0%

Last SUE: 0.19
Qual. Beats: 0

Revenue

Rev. CAGR: -4.39%
Rev. Trend: -14.8%

Last SUE: 0.35
Qual. Beats: 0

Dividends

Dividend Yield	5.91%
Yield on Cost 5y	3.72%
Yield CAGR 5y	2.03%
Payout Consistency	72.1%
Payout Ratio	73.6%

Risk via 5d forecast
Volatility	23.8%
Value at Risk 5%th	38.5%
Relative Tail Risk	-1.61%

Reward TTM
Sharpe Ratio	-1.75
Alpha	-38.38
CAGR/Max DD	-0.17

Character TTM
Hurst Exponent	0.465
Beta	0.217
Beta Downside	0.166

Drawdowns 3y
Max DD	40.45%
Mean DD	15.24%
Median DD	14.47%

Description: CLX The Clorox January 03, 2026

The Clorox Company (NYSE:CLX) is a diversified consumer-goods firm that markets cleaning, hygiene, and home-care products worldwide through four operating segments: Health & Wellness, Household, Lifestyle, and International. Its flagship brands include Clorox, Pine-Sol, Glad, Kingsford, Brita, Burt’s Bees, and Hidden Valley, covering everything from bleach and disinfectants to cat litter, food-service dressings, and water-filtration systems.

In FY 2023 the company generated roughly $8.8 billion in revenue, delivering an adjusted operating margin of about 15 % and a free-cash-flow conversion rate near 70 %. CLX maintains a dividend yield of ~2.6 % and has returned over $2 billion to shareholders via buybacks and dividends in the past three years, reflecting its strong cash generation and commitment to capital allocation.

Key economic drivers for Clorox include persistent consumer demand for hygiene and cleaning products-accelerated by the COVID-19 pandemic-and the ability to pass through inflationary cost pressures, given its pricing power in the household-products sector, which is projected to grow at a modest 3 % CAGR through 2027. Additionally, sustainability trends are boosting sales of reusable water-filtration (Brita) and natural personal-care (Burt’s Bees) lines, providing incremental growth avenues.

For a deeper quantitative view of CLX’s valuation metrics, the ValueRay platform offers a concise dashboard.

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (791.0m TTM) > 0 and > 6% of Revenue (6% = 406.3m TTM)

FCFTA 0.12 (>2.0%) and ΔFCFTA -0.67pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -7.96% (prev -0.04%; Δ -7.92pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 853.0m > Net Income 791.0m (YES >=105%, WARN >=100%)

Net Debt (2.91b) to EBITDA (1.33b) ratio: 2.19 <= 3.0 (WARN <= 3.5)

Current Ratio 0.76 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (123.0m) change vs 12m ago -1.33% (target <= -2.0% for YES)

Gross Margin 44.14% (prev 44.28%; Δ -0.13pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 122.8% (prev 135.9%; Δ -13.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 10.79 (EBITDA TTM 1.33b / Interest Expense TTM 103.0m) >= 6 (WARN >= 3)

Altman Z'' 0.87

(A) -0.10 = (Total Current Assets 1.70b - Total Current Liabilities 2.23b) / Total Assets 5.53b

(B) 0.04 = Retained Earnings (Balance) 200.0m / Total Assets 5.53b

(D) 0.03 = Book Value of Equity 166.0m / Total Liabilities 5.39b

Total Rating: 0.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 68.25

1. Piotroski 5.50pt

2. FCF Yield 4.15%

3. FCF Margin 9.39%

4. Debt/Equity data missing

5. Debt/Ebitda 2.19

6. ROIC - WACC (= 26.28)%

7. RoE data missing

8. Rev. Trend -14.81%

9. EPS Trend 45.97%

What is the price of CLX shares?

As of January 09, 2026, the stock is trading at USD 104.25 with a total of 2,097,510 shares traded.
Over the past week, the price has changed by +3.37%, over one month by +3.29%, over three months by -11.92% and over the past year by -32.66%.

Is CLX a buy, sell or hold?

The Clorox has received a consensus analysts rating of 3.05. Therefor, it is recommend to hold CLX.

Strong Buy: 2
Buy: 2
Hold: 13
Sell: 3
Strong Sell: 1

What are the forecasts/targets for the CLX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	120.9	16%
Analysts Target Price	120.9	16%
ValueRay Target Price	101.7	-2.4%

CLX Fundamental Data Overview January 09, 2026

P/E Trailing = 15.8012
P/E Forward = 16.8919
P/S = 1.8332
P/B = 46.5805
P/EG = 3.4454
Beta = 0.575
Revenue TTM = 6.77b USD
EBIT TTM = 1.11b USD
EBITDA TTM = 1.33b USD
Long Term Debt = 2.48b USD (from longTermDebt, last quarter)
Short Term Debt = 307.0m USD (from shortTermDebt, last quarter)
Debt = 3.08b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.91b USD (from netDebt column, last quarter)
Enterprise Value = 15.32b USD (12.41b + Debt 3.08b - CCE 166.0m)
Interest Coverage Ratio = 10.79 (Ebit TTM 1.11b / Interest Expense TTM 103.0m)
FCF Yield = 4.15% (FCF TTM 636.0m / Enterprise Value 15.32b)
FCF Margin = 9.39% (FCF TTM 636.0m / Revenue TTM 6.77b)
Net Margin = 11.68% (Net Income TTM 791.0m / Revenue TTM 6.77b)
Gross Margin = 44.14% ((Revenue TTM 6.77b - Cost of Revenue TTM 3.78b) / Revenue TTM)
Gross Margin QoQ = 41.57% (prev 46.33%)
Tobins Q-Ratio = 2.77 (Enterprise Value 15.32b / Total Assets 5.53b)
Interest Expense / Debt = 0.84% (Interest Expense 26.0m / Debt 3.08b)
Taxrate = 23.36% (25.0m / 107.0m)
NOPAT = 851.4m (EBIT 1.11b * (1 - 23.36%))
Current Ratio = 0.76 (Total Current Assets 1.70b / Total Current Liabilities 2.23b)
Debt / Equity = -139.9 (out of range, set to none) (Debt 3.08b / totalStockholderEquity, last quarter -22.0m)
Debt / EBITDA = 2.19 (Net Debt 2.91b / EBITDA 1.33b)
Debt / FCF = 4.58 (Net Debt 2.91b / FCF TTM 636.0m)
Total Stockholder Equity = 71.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.35% (Net Income 791.0m / Total Assets 5.53b)
RoE = 1110 % (out of range, set to none) (Net Income TTM 791.0m / Total Stockholder Equity 71.2m)
RoCE = 43.46% (EBIT 1.11b / Capital Employed (Equity 71.2m + L.T.Debt 2.48b))
RoIC = 31.87% (NOPAT 851.4m / Invested Capital 2.67b)
WACC = 5.59% (E(12.41b)/V(15.49b) * Re(6.82%) + D(3.08b)/V(15.49b) * Rd(0.84%) * (1-Tc(0.23)))
Discount Rate = 6.82% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.64%
[DCF Debug] Terminal Value 87.07% ; FCFF base≈649.2m ; Y1≈701.2m ; Y5≈867.8m
Fair Price DCF = 185.8 (EV 25.57b - Net Debt 2.91b = Equity 22.66b / Shares 122.0m; r=6.0% [WACC]; 5y FCF grow 9.04% → 3.0% )
EPS Correlation: 45.97 | EPS CAGR: 6.98% | SUE: 0.19 | # QB: 0
Revenue Correlation: -14.81 | Revenue CAGR: -4.39% | SUE: 0.35 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.57 | Chg30d=-0.001 | Revisions Net=-1 | Analysts=14
EPS current Year (2026-06-30): EPS=5.98 | Chg30d=-0.012 | Revisions Net=-1 | Growth EPS=-22.5% | Growth Revenue=-8.6%
EPS next Year (2027-06-30): EPS=6.75 | Chg30d=-0.021 | Revisions Net=-2 | Growth EPS=+12.8% | Growth Revenue=+4.7%

Additional Sources for CLX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle